Navigation Links
Lymph Node Test Doesnt Improve Breast Cancer Care, Study Finds

By Maureen Salamon
HealthDay Reporter

TUESDAY, July 26 (HealthDay News) -- A lymph node-sparing test hailed as revolutionary for its conservative approach does not lead to longer survival times for women undergoing lumpectomies whose early-stage breast cancer has spread microscopically, a large, new study suggests.

Examining the medical records of more than 5,200 patients who underwent breast-conserving surgery for early, invasive breast cancer, researchers found that tiny cancer cells in the sentinel lymph node -- the first node to which malignant cells are likely to spread from a primary tumor -- detected with a diagnostic procedure called immunohistochemical (IHC) staining had no effect on overall survival.

The biopsy procedure known as sentinel lymph node (SLN) dissection has been praised for averting the removal of large numbers of armpit lymph nodes during breast cancer surgery, which can lead to a painful buildup of fluid called lymphedema.

"I think I'd have to say it was highly controversial whether these occult [hidden] metastases would be clinically relevant," said study author Dr. Armando Giuliano, chief of surgical oncology at Cedars-Sinai Medical Center in Los Angeles. "If it's not going to affect mortality, it shouldn't affect treatment."

The study is published in the July 27 issue of the Journal of the American Medical Association.

The observational study included data from women included in the American College of Surgeons Oncology Group trial at 126 sites from May 1999 to May 2003, and all patients were followed until April 2010. Results were blinded to treating physicians to avoid the bias of overtreatment, Giuliano said.

At a midpoint follow-up of 6.3 years, 435 women had died and 376 experienced recurrence of their cancer. Based on IHC staining, five-year overall survival rates of those whose samples tested positive for node involvement were 95.1 percent, compared to 95.7 percent for those whose SLN biopsies tested negative. Corresponding five-year rates of disease-free survival were 90.4 percent and 92.2 percent, respectively.

Giuliano said the research, when adopted clinically, can save patients several hundred dollars or more in unnecessary tests. Women with microscopic metastases in their SLNs can also be spared from certain more aggressive treatments that were thought to increase their survival rates, he said.

Dr. Lora Weiselberg, chief of breast cancer service at the Monter Cancer Center of North Shore-LIJ Health System in Lake Success, N.Y., said many physicians have questioned the significance of the SLN biopsies evaluated in the study.

"In certain cases . . . we would want to do them anyway, but otherwise I think this is very strong evidence," Weiselberg said. "I think more and more pathology laboratories are going to go in that direction [of fewer tests] because adding another costly test, if it's not going to help the patient, is unnecessary."

More information

The U.S. National Cancer Institute has more on sentinel lymph node biopsies.

SOURCES: Armando Giuliano, M.D., chief, surgical oncology, and executive vice chair, surgery for surgical oncology, Cedars-Sinai Medical Center, Los Angeles; Lora Weiselberg, M.D., chief, breast cancer service, Monter Cancer Center, North Shore-LIJ Health System, Lake Success, N.Y.; July 27, 2011, Journal of the American Medical Association

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Tumors hide out from the immune system by mimicking lymph nodes
2. Specific lymph node radiotherapy is well tolerated after surgery in early breast cancer patients
3. New class of drug kills lymphoma cells
4. Routine breast cancer biopsy might predict lymph node cancer spread
5. Vitamin K may protect against developing non-Hodgkins lymphoma, say Mayo Clinic researchers
6. The Cancer Help Store Debuts New Blog with Information About Lymphedema and Cancer
7. Scott & White Healthcare clinical trials target lymphoma, leukemia
8. Lifestyle factors significantly impact survival of non-Hodgkins lymphoma patients, study finds
9. Lifestyle Affects Survival in Non-Hodgkins Lymphoma
10. Study identifies promising treatment for aggressive lymphoma
11. Pitt researchers discover gene mutation linked to lymphatic dysfunction
Post Your Comments:
Related Image:
Lymph Node Test Doesnt Improve Breast Cancer Care, Study Finds
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology: